---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000967"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T16:15:14.789125+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCryst FY2023 ORLADEYO rev $326M (+30% yoy); guides $380-400M 2024, expects operating profit

## Summary
- ORLADEYO net revenue $90.9M Q4, $326M FY2023; U.S. patients on paid/free product 1,104 (+30% yoy).
- 2024 guidance: ORLADEYO revenue $380-$400M; expects operating profit in 2024, positive EPS and cash flow in 2H 2025.
- GAAP net loss Q4 $61.7M ($0.31), FY2023 $226.5M ($1.18); non-GAAP net loss Q4 $56.4M ($0.28).
- R&D expenses fell to $70.1M Q4 (-4% yoy); SG&A rose to $64.4M Q4 (+28% yoy) on commercial expansion.
- Cash $390.8M at Dec 31, 2023; net cash use $8.6M in Q4.

## SEC filing metadata
- accession: 0001171843-24-000967
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184324000967/0001171843-24-000967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184324000967/f8k_022624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000967
- JSON: https://secwatch.observer/filing/0001171843-24-000967.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000967.txt

## Key facts
- Earnings Releases
  BIOCRYST PHARMACEUTICALS INC updated its the fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).
  - Period: the fourth quarter and full year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On February 26, 2024, BioCryst Pharmaceuticals, Inc. (the “Company”) issued a press release announcing recent corporate developments and its financial results for the fourth quarter and full year ended December 31, 2023, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184324000967/0001171843-24-000967-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.